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regularly in HCV patients
undergoing dialysis for ESRD
Sofosbuvir/velpatasvir is a
combination antiviral that is
approved for treatment
of HCV patients
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This study evaluated the safety
and efficacy of sofosbuvir/
velpatasvir in these patients 
Treatment with sofosbuvir/
velpatasvir was safe and
well tolerated
With a cure rate of 95%
in patients with HCV
infection and ESRD
Highlights
 Sofosbuvir/velpatasvir (SOF/VEL) is approved for patients
with HCV infection.
 There is no dosing recommendation for SOF-based regimens
for HCV-infected patients on dialysis.
 We evaluated SOF/VEL for 12 weeks in HCV-infected patients
with end-stage renal disease on dialysis.
 SOF/VEL was safe and well tolerated, with a cure rate of 95%
in our study.Sergio M. Borgia, Janet Dearden, Eric M.
Yoshida, ..., Yoav Lurie, Jose Luis Calleja,
Edward J. Gane
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Lay summary
Sofosbuvir/velpatasvir is a combination
direct-acting antiviral that is approved for
treatment of patients with hepatitis C
virus (HCV) infection. Despite the lack of
dosing recommendations, sofosbuvir-
containing regimens (including sofosbu-
vir/velpatasvir) are frequently used for
HCV-infected patients undergoing dialy-
sis. This study evaluated the safety and
efficacy of sofosbuvir/velpatasvir for
12 weeks in patients with HCV infection
who were undergoing dialysis. Treatment
with sofosbuvir/velpatasvir was safe and
well tolerated, resulting in a cure rate of
95% in patients with HCV infection and
end-stage renal disease.Viral Hepatitis. This is an open access article under the CC BY-NC-ND
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Background & Aims: Although off-label use of sofosbuvir-
containing regimens occurs regularly in patients with hepatitis
C virus (HCV) infection undergoing dialysis for severe renal
impairment or end-stage renal disease (ESRD), these regimens
are not licensed for this indication, and there is an absence of
dosing recommendations in this population. This study evalu-
ated the safety and efficacy of sofosbuvir/velpatasvir in patients
with HCV infection with ESRD undergoing dialysis.
Methods: In this phase II, single-arm study, 59 patients with
genotype 1–6 HCV infection with ESRD undergoing hemodialy-
sis or peritoneal dialysis received open-label sofosbuvir/
velpatasvir (400 mg/100 mg) once daily for 12 weeks. Patients
were HCV treatment naive or treatment experienced without
cirrhosis or with compensated cirrhosis. Patients previously
treated with any HCV NS5A inhibitor were not eligible. The pri-
mary efficacy endpoint was the proportion of patients achieving
sustained virologic response (SVR) 12 weeks after discontinua-
tion of treatment (SVR12). The primary safety endpoint was
the proportion of patients who discontinued study drug due
to adverse events.
Results: Overall, 56 of 59 patients achieved SVR12 (95%; 95% CI
86–99%). Of the 3 patients who did not achieve SVR12, 2
patients had virologic relapse determined at post-treatment
Keywords: Direct-acting antiviral; ESRD; Severe renal impairment; Chronic hepatitis
C infection; HCV, SVR12, drug safety.
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Week 4 (including 1 who prematurely discontinued study treat-
ment), and 1 patient died from suicide after achieving SVR
through post-treatment Week 4. The most common adverse
events were headache (17%), fatigue (14%), nausea (14%), and
vomiting (14%). Serious adverse events were reported for 11
patients (19%), and all were deemed to be unrelated to sofosbu-
vir/velpatasvir.
Conclusions: Treatment with sofosbuvir/velpatasvir for
12 weeks was safe and effective in patients with ESRD undergo-
ing dialysis.
Lay summary: Sofosbuvir/velpatasvir is a combination direct-
acting antiviral that is approved for treatment of patients with
hepatitis C virus (HCV) infection. Despite the lack of dosing rec-
ommendations, sofosbuvir-containing regimens (including
sofosbuvir/velpatasvir) are frequently used for HCV-infected
patients undergoing dialysis. This study evaluated the safety
and efficacy of sofosbuvir/velpatasvir for 12 weeks in patients
with HCV infection who were undergoing dialysis. Treatment
with sofosbuvir/velpatasvir was safe and well tolerated, result-
ing in a cure rate of 95% in patients with HCV infection and end-
stage renal disease.
Clinical Trial Number: NCT03036852.
 2019 European Association for the Study of the Liver. Published by
Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Hepatitis C virus (HCV) infection is a global health challenge
with an estimated 71 million individuals infected worldwide.1019 vol. 71 j 660–665
JOURNAL 
OF HEPATOLOGYThe disease burden of HCV infection is due to progression of
chronic liver disease, which can lead to cirrhosis, liver failure,
hepatocellular carcinoma, and death. Chronic HCV infection is
also independently associated with the development of renal
impairment referred to as chronic kidney disease (CKD) and
has been shown to be more prevalent in patients with renal dis-
ease.2,3 Chronic HCV infection has a significant negative impact
on morbidity and mortality in patients undergoing dialysis.4
HCV-infected patients with CKD have an accelerated rate of loss
of kidney function, risk of progression to end-stage renal disease
(ESRD), and increased risk of all-cause mortality when undergo-
ing dialysis.2,5–7
Over the last 2 years, direct-acting antiviral agents have been
approved for use in patients with HCV infection and CKD. How-
ever, approved HCV treatments for patients with ESRD are asso-
ciated with drug-drug interactions, baseline resistance testing,
risk of hepatotoxicity, and contraindication for those with
decompensated liver disease.8–10 Additionally, some of these
regimens are not pangenotypic.
Treatment regimens containing the NS5B inhibitor, sofosbu-
vir, are the most widely prescribed treatments for HCV infection
worldwide. The predominant circulating metabolite of sofosbu-
vir, GS-331007, is renally cleared and accumulates in patients
with severe renal impairment or ESRD, which has resulted in
the exclusion of this population in prior clinical trials, and con-
sequently, a lack of dosing recommendations for patients with
ESRD. However, real-world case series in patients with ESRD
undergoing dialysis demonstrate substantial use of sofosbuvir-
based regimens in this population, with no safety concerns
identified.11–17
The fixed-dose combination of sofosbuvir and velpatasvir, an
NS5A inhibitor, provides a treatment option for HCV-infected
patients regardless of HCV genotype, patient demographics,
and other disease characteristics.18,19 The current study evalu-
ated the safety and efficacy of sofosbuvir/velpatasvir in patients
with ESRD who were undergoing dialysis to expand our knowl-
edge regarding the use of sofosbuvir-based regimens in these
patients with severe renal impairment and ESRD.
Patients and methods
Patients
Patients were enrolled between 19 April 2017 and 28 Febru-
ary 2018 at 22 sites in Canada, the United Kingdom, Spain,
Israel, New Zealand, and Australia (ClinicalTrials.gov number,
NCT03036852). Eligible patients were men and women, at
least 18 years of age, with chronic genotype 1–6 HCV infec-
tion who were undergoing peritoneal dialysis or hemodialysis
for ESRD. HCV treatment-naive or treatment-experienced
patients without cirrhosis or with compensated cirrhosis were
eligible. Patients previously treated with any HCV NS5A inhi-
bitor were not eligible. The presence of cirrhosis was deter-
mined by a transient elastography (FibroScan [Echosens,
Paris, France]) result ≤12.5 kPa, liver biopsy (Metavir stage 4
or Ishak stage 5 or 6), or a FibroTest (BioPredictive S.A.S.,
Paris, France) result ≥0.75 at screening. Patients with HIV
infection were eligible if they were suppressed on a stable
antiretroviral regimen for at least 8 weeks prior to screening.
A full list of eligibility criteria is provided in the supplemen-
tary information. All patients provided written informed
consent.
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In this phase II, open-label study, patients were enrolled to
receive sofosbuvir/velpatasvir 400 mg/100 mg tablet18,19 once
daily for 12 weeks. Assessments were performed at screening
and baseline; on-treatment Weeks 2, 4, 8, and 12; and post-
treatment Weeks 4 and 12.
The study design was approved by an independent ethics
committee at each participating site (supplementary informa-
tion) and was conducted in compliance with the principles of
the Declaration of Helsinki, Good Clinical Practice guidelines,
and local regulatory requirements. The study was designed
and conducted according to the protocol by Gilead Sciences in
collaboration with the academic investigators.
Study procedures and assessments
Serum HCV RNA was measured using the COBAS AmpliPrep/
COBAS TaqMan HCV Quantitative Test, v2.0 (Roche Molecular
Diagnostics, Pleasanton, CA, USA) with a lower limit of quantita-
tion (LLOQ) of 15 IU/ml. HCV genotype and subtype were deter-
mined using the Siemens VERSANT HCV Genotype INNO-LiPA
2.0 assay (Siemens Healthcare GmbH, Erlangen, Germany) or
NS5B Sanger sequencing methods. For patients who were
unable to be genotyped using these methods, genotype and sub-
type were determined by basic local alignment search tool
(BLAST) analysis of NS5A and NS5B sequences.
Deep sequencing of the HCV NS5A and NS5B coding regions
was performed by DDL Diagnostic Laboratory (Rijswijk, the
Netherlands) on all patients in the Resistance Analysis Popula-
tion (i.e., patients with virologic outcomes and at least 1 gene
sequenced) to detect resistance-associated substitutions (RASs)
present at baseline and again for patients with virologic failure
to detect treatment-emergent RASs. RASs were defined as speci-
fic substitutions that either confer a reduced susceptibility to
drugs of the given class with a >2.5-fold change in half-
maximal effective concentration compared with a genotype-
specific reference in a replicon model, or that commonly select
in patients with virologic failure at the time of relapse
(Table S1). All RASs are presented using a 15% assay cut-off.
Safety assessments included monitoring of adverse events,
clinical laboratory tests, and vital sign measurements at base-
line and all on-treatment and post-treatment visits. Physical
examinations were performed at baseline, Week 12, and all
post-treatment visits.
For pharmacokinetics (PK) evaluation, a single blood sample
was collected from all patients at the on-treatment Weeks 2, 4,
6, 8, and 12 visits. For patients who consented to participate in
an optional intensive PK substudy, blood samples were col-
lected at the on-treatment Week 6, 8, or 12 visit at the following
time points: predose and 0.25, 0.5, 1, 2, 4, 6, 8, 10, and 12 hours
postdose. Plasma concentrations of sofosbuvir, sofosbuvir
metabolites GS-566500 and GS-331007, and velpatasvir were
determined using fully validated high-performance liquid
chromatography-tandem mass spectroscopy bioanalytical
methods.
Statistical analyses
The primary efficacy endpoint was the proportion of patients
who achieved sustained virologic response (SVR) (i.e., HCV
RNA <15 IU/ml) 12 weeks after discontinuation of sofosbuvir/
velpatasvir (SVR12). The SVR12 rates and two-sided 95% exact
CIs were calculated for study patients overall and by HCV
019 vol. 71 j 660–665 661
genotype and subtype using the Clopper-Pearson method.20 The
emergence of viral resistance was also evaluated. The primary
safety endpoint was the proportion of patients who discontin-
ued study drug due to adverse events. The steady-state, pre-
dialysis exposures of sofosbuvir, GS-331007, and velpatasvir
were estimated based on population PK analysis. These PK
exposure parameters were then compared to those observed
in HCV-infected patients without renal impairment (estimated
glomerular filtration rate >90 ml/min) who were treated with
sofosbuvir/velpatasvir in phase II/III studies. Phoenix WinNonlin
version 6.3 (Pharsight Corporation, Mountain View, CA, USA)
was used to perform the PK data analyses.
SAS software version 9.4 (SAS Institute, Cary, NC, USA) was
used to perform the statistical analyses.
Because of the exploratory nature of this study, no formal
power calculations were performed to determine sample size;
the sample size of 100 patients was selected for practical
patients did not meet eligibility criteria, and 2 patients met
eligibility criteria but were not enrolled because their screen-
ing visits were outside the visit window (Table S2). The mean
(range) age of patients was 60 (33–91) years; 59% of patients
were male, and 29% had cirrhosis. Most patients had genotype
1 (46% [25% 1a and 19% 1b]) or 3 (32%) HCV infection; 12%
had genotype 2, 7% had genotype 4, and 3% had genotype 6
HCV infection. The mean (range) baseline HCV RNA level
was 5.8 (3.1–7.7) log10 IU/ml. Fifty-four of the 59 patients
enrolled (92%) were undergoing hemodialysis, with a mean
(range) dialysis duration of 7 (0–40) years, while the other
5 patients (8%) were undergoing peritoneal dialysis. As
expected in this population, the majority of patients had mul-
tiple comorbidities. Overall, 90% of patients had underlying
vascular disorders, primarily hypertension; 37% had underly-
ing cardiac disorders, including coronary artery disease, car-
diac failure, or cardiomyopathy; and 32% had diabetes
mellitus. During the study, 53% of patients were taking cal-
cium channel blockers and 47% of patients were taking beta
blockers. Additionally, 37% of patients were taking proton-
pump inhibitors during the study, which is also common in
the dialysis population.
Efficacy
Overall, 56 of 59 patients achieved SVR12 (95%; 95% CI 86–
99%) following 12 weeks of once-daily treatment with sofos-
buvir/velpatasvir (Table 2). Of the patients who achieved
SVR12, 53 patients had study drug adherence rates of ≥90%
as measured by pill counts, and 3 patients, who did not return
all their study drug bottles, had study drug adherence rates of
without cirrhosis (this patient was discontinued from the
Research Article Viral Hepatitisreasons.
For additional details regarding the methods used, please
refer to the Supplementary CTAT Table.
Results
Patient characteristics
Seventy-eight patients were screened from 22 March 2017
through 14 February 2018 at 22 sites in Canada, the United
Kingdom, Spain, Israel, New Zealand, and Australia. Fifty-
nine patients were enrolled and received at least 1 dose of
sofosbuvir/velpatasvir, including 46 (78%) treatment-naive
and 13 (22%) treatment-experienced patients (Table 1). Of
the 19 patients who were screened and not enrolled, 17
Table 1. Baseline demographics and disease characteristics.
Sofosbuvir/velpatasvir
for 12 weeks (n = 59)
Mean age (range), yr 60 (33–91)
Male, n (%) 35 (59)
Race, n (%)
White 31 (53)
Asian 18 (31)
Black or African American 6 (10)
American Indian or Alaska Native 2 (3)
Native Hawaiian or Pacific Islander 2 (3)
Mean body mass index (range), kg/m2 26 (17–39)
HCV genotype, n (%)
1 27 (46)
1a 15 (25)
1b 11 (19)
Other 1 (2)
2 7 (12)
3 19 (32)
4 4 (7)
6 2 (3)
Cirrhosis, n (%) 17 (29)
Mean HCV RNA level (range), log10 IU/ml 5.8 (3.1–7.7)
Prior HCV treatment experience, n/N (%) 13/59 (22)
Direct-acting antiviral-naive
Pegylated interferon + ribavirin 6//13 (46)
Other 7/13 (54)
Type of dialysis, n (%)
Hemodialysis 54 (92)
Peritoneal dialysis 5 (9)
Mean duration of dialysis (range), yr 7 (0–40)
Prior renal transplant, n (%) 19 (32)
HCV, hepatitis C virus.662 Journal of Hepatology 2<90% due to the imputation of missed pills. Of the 3 patients
who did not achieve SVR12, 2 patients had virologic relapse
determined at post-treatment Week 4, including 1
treatment-experienced patient with genotype 3a HCV and cir-
rhosis and 1 treatment-naive patient with genotype 1b HCVstudy after 11 weeks of treatment due to nonadherence with
study drug). The latter patient had a study drug adherence
rate of 48% as measured by pill counts and low plasma con-
centrations of GS-331007 at on-treatment Week 8, consistent
with nonadherence with study drug dosing. The third patient
who did not achieve SVR12 died from suicide after achieving
viral suppression at the post-treatment Week 4 visit.
Plasma levels of HCV RNA declined rapidly with treatment,
with all patients (100.0%; 95% CI 94–100%) having HCV RNA <
LLOQ after 4 weeks of treatment (Fig. 1). No patients experi-
enced on-treatment virologic failure.
Viral resistance
A total of 58 patients (98%) were included in the resistance anal-
ysis population. At baseline, 32% of patients had NS5A RASs, and
Table 2. Treatment response.
Sofosbuvir/velpatasvir
for 12 weeks (n = 59)
SVR12, n (%) 56 (95)
Overall virologic failure, n (%) 2 (3)
Relapse 2 (3)
On-treatment virologic failure 0
Other, n (%) 1 (2)
SVR12, sustained virologic response rate 12 weeks after discontinuation of
treatment.019 vol. 71 j 660–665
HCV-infected patients with ESRD undergoing dialysis compared
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Table 3. Adverse events and laboratory abnormalities.
Sofosbuvir/velpatasvir for
12 weeks (n = 59)
Any adverse event, n (%) 47 (80)
Grade 3 adverse events, n (%)a 7 (12)
Serious adverse events, n (%)b 11 (19)
Adverse events leading to sofosbuvir/
velpatasvir discontinuation, n (%)
0
Deaths, n (%) 2 (3)
Adverse events occurring in ≥ 10% of patients, n (%)
Headache 10 (17)
Fatigue 8 (14)
Nausea 8 (14)
Vomiting 8 (14)
Insomnia 6 (10)
Grade 3 or 4 laboratory abnormalities in > 1 patient, n (%)
Creatinine
coccal bacteremia; all unrelated to study treatment.
c All in patients with ongoing diabetes.
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OF HEPATOLOGY12% of patients had NS5B nucleoside inhibitor (NI) RASs
(Table S3). Overall, 94% of patients with baseline NS5A RASs
and 97% of patients without baseline NS5A RASs achieved
SVR12. The treatment-experienced patient with genotype 3a
HCV infection and cirrhosis with virologic failure had the
NS5A RAS Y93H at baseline and Y93H/Y at the time of relapse,
with no NS5B NI RASs detected at baseline or relapse. The
treatment-naive patient with genotype 1b HCV infection with-
out cirrhosis with virologic failure (who had poor adherence
with study drug) did not have NS5A or NS5B NI RASs detected
at baseline or relapse. No NS5A or NS5B NI RASs emerged in
either patient at the time of relapse.
Safety
Most patients experienced an adverse event (80%), the majority
of which were mild or moderate in severity (Table 3). The most
common adverse events (reported for ≥10% of patients) were
headache (17%), fatigue (14%), nausea (14%), vomiting (14%),
and insomnia (10%). Serious adverse events were reported for
11 patients (19%), and none were assessed as related to study
treatment. No adverse events associated with renal dysfunction
were reported. The only renal adverse events in this study
included Grade 1 increased daytime urinary frequency and
Grade 1 renal colic (1 patient each). No patients prematurely
discontinued sofosbuvir/velpatasvir due to adverse events.
Two deaths occurred during the study. One patient, who had a
history of anxiety, died from suicide 79 days after completing
study treatment, and 1 patient, who achieved SVR12 and had
a history of tobacco use, died of metastatic lung cancer 111 days
after completing study treatment.
The incidence of Grade 3 and 4 laboratory abnormalities was
consistent with patients with ESRD undergoing dialysis. The
only Grade 3 laboratory abnormalities observed in more than
1 patient were decreased hemoglobin (4 patients), hyper-
glycemia (5 patients), and hyperkalemia (2 patients). All 5
patients with hyperglycemia had diabetes, and 4 of these
patients were taking medication for diabetes. The only Grade
4 laboratory abnormality observed in more than 1 patient was
increased creatinine (14 patients), and abnormalities in crea-
tinine are anticipated in patients with ESRD undergoing dialysis.
Pharmacokinetics
Exposures (AUCtau) of sofosbuvir, GS-331007, and velpatasvir
were 81%, 1,719%, and 41% higher, respectively, in
Fig. 1. Mean (± SD) HCV RNA levels from baseline through end of
treatment. BL, baseline.Journal of Hepatology 2Grade 3 1 (2)
Grade 4 14 (24)
Hyperglycemiac
Grade 3 5 (9)
Hemoglobin
Grade 3 4 (7)
Hyperkalemia
Grade 3 2 (3)
Grade 4 1 (2)
a Cardiac failure congestive, device-related infection, headache, insomnia, neurilem-
moma benign, pneumonia, and pubis fracture; all unrelated to study treatment.
b Anxiety, atrial fibrillation, cardiac failure congestive, cellulitis, depression, device-
related infection, neurilemmoma benign, pneumonia, post procedural hemorrhage,
post procedural swelling, pubis fracture, respiratory tract infection, and strepto-with HCV-infected patients with normal renal function
(estimated glomerular filtration rate >90 ml/min) evaluated in
the sofosbuvir/velpatasvir phase II/III population (Table 4).
Discussion
In this multicenter, open-label study, treatment with sofosbu-
vir/velpatasvir for 12 weeks in HCV-infected patients with ESRD
undergoing dialysis resulted in an SVR12 rate of 95%.
Two patients had virologic failure: 1 patient relapsed with
NS5A resistance before and after completing treatment, and
1 patient, who was discontinued from study treatment due to
nonadherence with study drug dosing as assessed by pill counts
and PK data, relapsed without NS5A resistance. Treatment with
sofosbuvir/velpatasvir was generally safe and well tolerated,
with a safety profile consistent with that expected for patients
with ESRD undergoing dialysis. There were no treatment-
related discontinuations or serious adverse events.
Overall, the safety and efficacy results from this study are
consistent with those observed in the ASTRAL-1, ASTRAL-2,
ASTRAL-3, ASTRAL-5, POLARIS-2, and POLARIS-3 clinical trials
of sofosbuvir/velpatasvir, which demonstrated that treatment
with sofosbuvir/velpatasvir for 12 weeks was well tolerated
and resulted in high SVR rates across HCV genotypes in patients
with or without compensated cirrhosis.21–23 The safety profile
and response rates are also consistent with results from a phase
IIb study, which demonstrated that treatment of ledipasvir (an
NS5A inhibitor) combined with sofosbuvir once daily for
12 weeks in HCV-infected patients with ESRD was well toler-
ated and resulted in an SVR12 rate of 100%.24019 vol. 71 j 660–665 663
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Research Article Viral HepatitisPlasma exposures of sofosbuvir, GS-331007, and velpatasvir
were higher in HCV-infected patients with ESRD undergoing
dialysis compared with HCV-infected patients with normal
renal function. The increased exposure of GS-331007, the pre-
dominant circulating metabolite of sofosbuvir, was expected,
as it is renally cleared. These observations are also consistent
with results from a phase I study in HCV-negative patients with
varying degrees of renal impairment and ESRD, which showed
increased exposures of GS-331007 in patients with severe renal
Table 4. Steady-state sofosbuvir, GS-331007, and velpatasvir plasma pharm
with ESRD undergoing dialysis vs. HCV-infected patients with normal rena
PK parameter Mean
ESRD population Phase II/II
Sofosbuvir n = 21
AUCtau, hng/ml 2,382 (24)
Cmax, ng/ml 1,041 (17)
GS-331007 n = 59
AUCtau, hng/ml 230,989 (35)
Cmax, ng/ml 9,776 (35)
Velpatasvir n = 59
AUCtau, hng/ml 4,279 (51)
Cmax, ng/ml 227 (41)
%CV, percentage coefficient of variation; %GMR, percentage geometric mean ratio; Eimpairment, and even higher exposures in patients with ESRD.
These increases in exposure were not considered clinically rele-
vant as no exposure-response relationships for safety metrics
were observed. Additionally, real-world case series have
demonstrated substantial use of sofosbuvir-based regimens in
patients with ESRD with no safety concerns identified.11–17
Over the last few years, several HCV treatments have been
approved for use in patients with HCV infection and CKD, and
each regimen has limitations. For example, some of these treat-
ments require the addition of ribavirin for optimal efficacy in
many populations, and ribavirin-induced toxicities are exacer-
bated in patients with ESRD.8 Some components of these
approved treatments are associated with the potential for
drug-drug interactions, which adds increasing complexity to
the management of HCV-infected patients with ESRD who fre-
quently have multiple comorbid conditions and concomitant
medications.8 Some treatments also require baseline resistance
testing for patients with genotype 1a infection.10 Additionally,
these regimens involve the use of protease inhibitors, which
carry the risk of alanine aminotransferase elevations or hepato-
for Norgine. Conrado Fernandez Rodriguez has received hono-
raria from Gilead Sciences, AbbVie, and MSD, and his institutiontoxicity, especially in patients with hepatic decompensation.
These HCV protease inhibitor-containing regimens also have
drug-drug interaction potential with other substrates/inhibitors
of cytochrome P450, including some HIV antiretroviral thera-
pies and immunosuppressive medications, which are of clinical
relevance to the renal dialysis population.8–10 Finally, indica-
tions for some of these regimens are limited to patients with
HCV genotypes 1 and/or 4. Sofosbuvir/velpatasvir offers a
single-tablet, once daily, pangenotypic treatment for HCV in
patients with ESRD who are undergoing dialysis, including those
with hepatic decompensation.
The relatively low number of patients in some subgroups and
the exclusion of patients with decompensated liver disease may
limit the generalizability of our findings (supplementary infor-
mation). Another limitation was the absence of a placebo-
controlled group to assist in distinguishing between adverse
events that were related to treatment from those arising as
sequelae of HCV infection, ESRD, or underlying comorbidities.
664 Journal of Hepatology 2Additionally, the high SVR rate observed in this study precludes
meaningful analysis of patient subgroups.
The data collected in this study provide information to sup-
port the use of sofosbuvir/velpatasvir in HCV-infected patients
with ESRD. The results from this study also support the applica-
bility of this data in patients with severe renal impairment and
the use of sofosbuvir/velpatasvir in this population with no
additional safety risks. In conclusion, the single-tablet, pangeno-
typic regimen of sofosbuvir/velpatasvir for 12 weeks is a safe,
well tolerated, and highly effective treatment option for HCV-
infected patients undergoing dialysis for ESRD.
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